Buy or sell AOBiome stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

AOBiome Stock

Life Sciences Company

Founded

2013

Notable Investors

iCarbonX

Headquarters

Cambridge MA, US

Total Funding

$38.7M

About AOBiome Stock

AOBiome is a life sciences company that focuses on transforming human health by developing microbiome-based therapies for inflammatory conditions. The company's portfolio includes multiple clinical-stage programs; a completed Phase 2 study to treat patients with acne vulgaris or acne, a Phase 1b study to treat patients with pediatric eczema (atopic dermatitis), a Phase 2a study to treat patients with adult eczema (atopic dermatitis), a Phase 2 study for the prevention of episodic migraines, and a Phase 1b/2a clinical trial for the treatment of allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. Its product candidates harness a single strain of class-defining, auto-regulating Ammonia Oxidizing Bacteria (AOB), a human commensal, enabling healthcare practitioners to produce well-understood and well-characterized biochemical compound that are critical to human health. AOBiome was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Investors

Hedgewood

Plastiq, AOBiome

iCarbonX

AOBiome

Wakestream Ventures

AOBiome

Funding History

March 2013$630K
August 2014$577K
December 2014$7.5M
January 2017$30.0M

Management

Chief Executive Officer

Todd Krueger

Press

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from AOBiome or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 130K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo